Nilutamide-d6

Nilutamide-d6 (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma[1][2].

Product Specifications

CAS Number

[1189477-66-4]

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H319

Target

Androgen Receptor; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.77

Solubility

10 mM in DMSO|DMSO : ≥ 8.08mg/mL|Ethanol : ≥ 8.08mg/mL

Smiles

O=C1N(C2=CC(C(F)(F)F)=C(C=C2)[N+]([O-])=O)C(NC1(C([2H])([2H])[2H])C([2H])([2H])[2H])=O

Molecular Formula

C12H4D6F3N3O4

Molecular Weight

323.26

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Harris MG, et al. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1993 Jan-Feb;3 (1) :9-25.|[3]Ask K, et al. Metabolism of nilutamide in rat lung. Biochem Pharmacol. 2006 Jan 12;71 (3) :377-85.